On April 10, 2024, Vertex Pharmaceuticals ("Vertex") and Alpine Immune Sciences ("Alpine") announced that the parties entered into a definitive agreement. the parties have entered into a definitive agreement.
On April 12, 2024, Arvinas announced that it has entered into an exclusive strategic license agreement with Novartis to collaborate on the development of Arvinas' second-generation androgen receptor (AR) degrader, ARV-766.
On February 28th, US-based Viatris and Swiss firm Idorsia launched a major R&D partnership, with Viatris securing exclusive global rights for two Phase 3 drugs, Selatogrel and Cenerimod, and options for future joint projects.
clinical-stage biopharma atai Life Sciences (NASDAQ: ATAI), focused on transforming mental health treatment, announced a strategic investment in Beckley Psytech, cementing its position as the bio-pharma leader with the broadest portfolio of clinical-stage psychedelic drug candidates.
On February 21, 2024, Innovent Biologics and ImmVirX unveiled a partnership for clinical research on a combo therapy using sintilimab and the cancer-fighting virus IVX037.